| Literature DB >> 32575811 |
Stefania Cicolari1, Marco Dacrema2, Arold Jorel Tsetegho Sokeng3, Jianbo Xiao4, Achille Parfait Atchan Nwakiban5, Carmen Di Giovanni2, Cristina Santarcangelo2, Paolo Magni1,6, Maria Daglia2,4.
Abstract
Metabolic syndrome includes a cluster of risk factors for many pathological conditions, including hyperglycemia, abdominal obesity, hyperlipidemia, and hypertension. Adansonia digitata L. (also known as baobab) is used in traditional African Medicine and recent studies showed that it improves the metabolism of carbohydrates and lipids. The aim of this study is to investigate the mechanisms of action associated with the beneficial effects of extracts from the edible parts of baobab (fruit pulp, leaves, raw and toasted seeds), evaluating their inhibitory activity against: alpha-amylase, alpha-glucosidase, angiotensin-converting enzyme, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, and pancreatic lipase. Baobab fruit pulp and leaf extracts resulted to be the most active ones and were then tested on the differentiation process of SW-872 human liposarcoma cells to mature adipocytes. The addition of these latter extracts did not affect triglyceride accumulation, indicating a neutral impact on this parameter. The findings here reported help to explain the growing amount of evidence on the biological properties of baobab and provide suggestions about their use in food and nutraceutical fields.Entities:
Keywords: ACE inhibition; Adansonia digitata L.; HMG-CoA reductase inhibition; SW-872 preadipocytes; baobab edible parts; digestive enzyme inhibition
Mesh:
Substances:
Year: 2020 PMID: 32575811 PMCID: PMC7356617 DOI: 10.3390/molecules25122858
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Inhibitory activity of extracts from baobab edible parts towards alpha-amylase (A) and alpha-glucosidase (B). The results are expressed as mean of percentage (%) inhibition (± SD). Acarbose was used as positive control. 1. Fruit pulp extract; 2. Leaf extract; 3. Raw seed extract 4. Toasted seed extract; 5. Acarbose. IC50 values are also reported. * means statistically significant difference (p < 0.05) between the two groups.
Figure 2Inhibition activity of extracts from baobab edible parts against ACE (A), HMGCoA-R (B), and pancreatic lipase (C). The results are expressed as mean of percentage (%) inhibition (± SD). Captopril, pravastatin, and orlistat were used as positive control at increasing concentrations. 1. Fruit pulp extract; 2. Leaf extract; 3. Raw seed extract; 4. Toasted seed extract; 5. Pravastatin. IC50 values are also reported. * means statistically significant difference (p < 0.05) between the two groups.
Figure 3Cytotoxicity activity of extracts from baobab edible parts in SW-872 cells (MTS assay) (A,B). Cells were differentiated with 100 μM oleic acid for 7 days and then were incubated for 24 (A) or 48 h (B) with plant extracts. Data are derived from pooling of two separate experiments (total n = 4) and are expressed as mean of percentage (%) inhibition (± SD). Effect of baobab extracts on adipocyte differentiation of SW-872 cells with oleic acid (ORO staining) (C). SW-872 cells were incubated for 7 days with 100 µM oleic acid, with or without 10 and 25 mg/mL baobab extracts. The red staining (ORO) indicates relevant triglyceride accumulation (marker of adipocyte differentiation) (inverted phase contrast microscopy; 20X magnification). The addition of 10 or 25 µg/mL baobab extracts to 100 µM oleic acid did not affect triglyceride accumulation. Control: Untreated SW-872 cells (preadipocytes). ABL: Baobab leaf extract; ABF: Baobab fruit pulp extract.
Effect of baobab leaf extract and baobab fruit pulp extract on triglyceride accumulation in SW-872 cells differentiated to adipocytes with 100 µM oleic acid (n = 3).
| Cell Treatment | mg/mL | % |
|---|---|---|
| Control | 1.318 (0.131) | 100 |
| Oleic acid | 2.821 (0.660) | 214 |
| Oleic acid + baobab leaf extract | 3.158 (0.281) | 240 |
| Oleic acid + baobab fruit pulp extract | 3.005 (0.213) | 228 |
Polyphenol binding sites characterization.
| Molecular | Catalytic | Allosteric | Residues | Ref. |
|---|---|---|---|---|
| Alpha-glucosidase | √ | R407, R197, R407, F282 | Jhong et al., 2015 [ | |
| Alpha-Amylase | √ | K200, E233, D300, W151, A198, L162 | Jhong et al., 2015 [ | |
| 3-Hydroxy-3-methylglutaryl-coenzyme A reductase | √ | K691, E559, D767 | Islam et al., 2015 [ | |
| Pancreatic Lipase | √ | F78, Y115, H152, F216 | Martinez Gonzales et al., 2017 [ | |
| Angiotensin-converting enzyme (ACE) | √ | S1′, S2′/S1′, S2′ regions | Guerrero et al., 2012 [ |
Figure 43D and 2D views of the quercetin and kaempferol pharmacophore models respectively (A,B). 3D and 2D views of the quercetrin and rutin pharmacophore models respectively (C,D). In the depictions, the features are encoded as AR = aromatic ring in blue.
Figure 5Merged pharmacophore of the compounds quercetin, kaempferol, quercitrin and rutin with features HBA (red spheres), HBD (green spheres) hydrophobic region (yellow sphere), aromatic ring (blue sphere), and volume excluded (gray spheres).